Business News

From March 18-20, 2023, the 2023 (15th) China Pharmaceutical Strategy Conference, co-hosted by the China Pharmaceutical Industry Information Center and the Shijiazhuang High-tech Industrial Development Zone Management Committee, was held in Shijiazhuang.

To visually and vividly present the policy system of the innovative drug industry and the spirit of innovative pharmaceutical companies under its development model, and to set a benchmark and contribute to the advancement of China’s innovative drug industry, on March 19, the lists of “2022 China’s Innovative Pharmaceutical Companies” and “2022 China’s Innovative CRO Companies” were announced at the 2023 (15th) Chinese Medical Strategy Conference. Haisco Medicine Group won the title of “2022 China’s Innovative Pharmaceutical Companies”.

Heisike Pharmaceutical Group has adhered to innovation-driven development over the years. It focuses on areas such as anesthesia and analgesia, diabetes and complications, neural pain, and tumors. The company accelerates the translation and implementation of scientific research results to promote high-quality development in the pharmaceutical industry. As of now, Heisike Pharmaceutical Group is currently researching 16 innovative drugs (14 first-class new drugs), and three first-class new drugs are expected to be launched in the market.

On the morning of March 19, Mr. Hou Xiyong, Deputy General Manager and Marketing General Manager of Hisco Pharmaceutical Group, participated in a roundtable discussion on response and strategy. He discussed with senior executives from Shiyao Group, North China Pharmaceutical, and Shijiazhuang Siyao how to "innovate and strengthen chains to support high-quality industrial development".

On the afternoon of March 19, Ms. Li Shaohui, Deputy General Manager of Marketing at Hisiko Pharmaceutical Group, participated in a roundtable discussion with experts and scholars such as Sun Lihua, Li Fen, and Tian Lei to discuss three issues related to "access and affordability of innovative drugs under medical insurance".

“With a spirit of struggle, walking alongside life,” Hisicor will cherish every life. With an innovative and practical approach to development, it focuses on patient recovery; it values every technology, continuously innovating efficiently to overcome technical barriers and transform them into medical achievements. With unremitting effort and a strong sense of responsibility, it protects health and life, earning full trust from society and the public, and contributing to improving health quality. This is the corporate mission of Hisicor Pharmaceutical Group.